A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
Status:
NOT_YET_RECRUITING
Trial end date:
2026-09-04
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with delamanid in combination with bedaquiline, linezolid, levofloxacin (moxifloxacin)/clofazimine, etc. in the treatment of patients with drug-resistant (including rifampicin-resistant) tuberculosis for 8 weeks.